Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01885689

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia. Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into a patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving clofarabine and melphalan before transplant may help prevent the cancer from coming back after transplant, and they may cause fewer side effects than standard treatment.

Status: 
Recruiting
Study Date: 
Wed, 01/01/2014 to Wed, 12/01/2021
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: clofarabine Given IV Other Names: CAFdA Clofarex Clolar Drug: melphalan Given IV Other Names: Alkeran CB-3025 L-PAM L-phenylalanine mustard L-Sarcolysin Procedure: allogeneic hematopoietic stem cell transplantation Undergo allogeneic hematopoietic stem cell transplant Drug: tacrolimus Given IV or PO Other Names: FK 506 Prograf Drug: sirolimus Given PO Other Names: AY 22989 Rapamune rapamycin SLM